JENA, Germany--(BUSINESS WIRE)--SIRS-Lab GmbH has announced the successful identification of new biomarker candidates for sepsis. The Jena biotechnology company which develops products for the diagnosis and therapy monitoring of life threatening infectious diseases has successfully completed a pivotal step in the development of early diagnosis tests for sepsis, an often deadly disease. These results emerged from a collaboration between SIRS-Lab GmbH, the University Clinics Jena and Analytik Jena AG within the BioChancePLUS Programme, supported by the German Federal Ministry for Education and Research..
